Showing results (161-170 of 223) with videos related to
Sort By:
Pageof 23
Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.JAMA Oncology|January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor TrialRaffit Hassan, Anish Thomas, John J Nemunaitis, et al.JAMA Oncology|September 23, 2018
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 StudyLeisha A Emens, Cristina Cruz, Joseph Paul Eder, et al.Journal for Immunotherapy of Cancer|June 7, 2020
Circulating CD14high CD16low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progressionMélissa Prat, Augustin Le Naour, Kimberley Coulson, et al.American Journal of Clinical Oncology|February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 StudyRoger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.Targeted Oncology|April 13, 2021
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib ProgramThomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, et al.Oncotarget|April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemiaNorbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.JAMA Oncology|November 8, 2019
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical TrialKimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.Plos One|December 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinomaBert H O'Neil, John M Wallmark, David Lorente, et al.Pageof 23